All In Biotech

Free tool

FAERS Monitor: Emgality

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761063 or its brand name (Emgality, Galcanezumab-Gnlm). Reports on generic versions are filed under their own applications.

Reports

32,317

Serious

4,007

12% of reports

Hospitalization

1,162

Death reported

89

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • injection site pain7,789
  • migraine3,158
  • underdose2,919
  • headache2,509
  • drug ineffective1,980
  • product dose omission issue1,766
  • injection site haemorrhage1,666
  • incorrect dose administered1,197
  • injection site erythema1,145
  • accidental underdose1,068
  • nausea852
  • injection site swelling827
  • injection site pruritus824
  • fatigue795
  • injection site reaction731

Reports by year received

View as table
YearReports
20154
20164
20176
2018140
20194,657
20206,640
20214,645
20223,737
20232,977
20243,150
20253,672
20262,685

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,021,842 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
accidental underdoseSignal1,06852.149.049,524
underdoseSignal2,91927.126.170,570
migraineSignal3,15822.221.562,180
injection site painSignal7,78916.916.6115,461
injection site haemorrhageSignal1,66613.813.219,499
injection site pruritusSignal8248.17.65,069
injection site swellingSignal8277.16.64,289
injection site reactionSignal7317.06.53,710
injection site erythemaSignal1,1456.15.74,810
product dose omission issueSignal1,7663.93.83,880
incorrect dose administeredSignal1,1973.43.22,065
headacheSignal2,5092.62.52,559
drug ineffective1,9801.00.91
nausea8520.70.7113
fatigue7950.70.6140

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.